[Severe adult asthma and treatment adherence: Results of the FASE-CPHG study]

Data on severe asthma in France are scarce. The aim of this study was to evaluate adherence to asthma treatments and its determinants in a population of severe asthmatics.From May 2016 to June 2017, the French Collège des Pneumologues des Hôpitaux Généraux organized a large-scale prospective, cross-sectional, multicenter study on this topic; 1502 patients with severe asthma were included.The average number of substantive treatments was 2.5±1.1. Assessed by self-questionnaire in 1289 patients, overall adherence was 64.8%, in good agreement with the findings of the pneumologist in charge (p0.0001). Control of asthma according to the GINA criteria was more successful in compliant patients (p0.01). In univariate analysis, the most compliant participants were frequent exacerbator patients (p=0.02), those with nasal polyposis (p=0.01) and those receiving an anticholinergic agent (p0.01), anti-IgE biotherapy (p0.0001) or oral corticosteroids (p0.01). The least compliant participants were younger (p0.0001), active smokers (p0.001), with shorter average disease duration (24.2±15.7 vs 29.1±18.7 years, p0.0001) and a lower number of substantive asthma treatments (2.2±1 vs 2.6±1, p0.0001). In multivariate analysis, age, length of disease and anti-IgE treatment were the only factors affecting therapeutic compliance.In this large-scale study of severe asthmatic patients, 64.8% were compliant according to the MMAS-4© self-administered questionnaire and appeared to be better monitored according to the criteria defined in our study. Overall, adherence was more satisfactory among older patients and those whose disease had been evolving over a long period of time or were receiving anti-IgE biotherapy.